CoChat

MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAFV600E amplification whereas KRASG13D amplification promotes EMT-chemoresistance

Open access
Sale, Matthew J., Balmanno, Kathryn, Saxena, Jayeta, Ozono, Eiko, Wojdyla, Katarzyna, McIntyre, Rebecca E., Gilley, Rebecca, Woroniuk, Anna, Howarth, Karen D., Hughes, Gareth, Dry, Jonathan R., Arends, Mark J., Caro, Pilar, Oxley, David, Ashton, Susan, Adams, David J., Saez-Rodriguez, Julio, Smith, Paul D., Cook, Simon J. · 2019 · Nature Communications
Cited by 52

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

Acquired resistance to MEK1/2 inhibitors (MEKi) arises through amplification of BRAF V600E or KRAS G13D to reinstate ERK1/2 signalling. Here we show that BRAF V600E amplification and MEKi resistance are reversible following drug withdrawal. Cells with BRAF V600E amplification are addicted to MEKi to maintain a precise level of ERK1/2 signalling that is optimal for cell proliferation and survival, and tumour growth in vivo. Robust ERK1/2 activation following MEKi withdrawal drives a p57 KIP2 -dependent G1 cell cycle arrest and senescence or expression of NOXA and cell death, selecting against those cells with amplified BRAF V600E . p57 KIP2 expression is required for loss of BRAF V600E amplification and reversal of MEKi resistance. Thus, BRAF V600E amplification confers a selective disadvantage during drug withdrawal, validating intermittent dosing to forestall resistance. In contrast, resistance driven by KRAS G13D amplification is not reversible; rather ERK1/2 hyperactivation drives ZEB1-dependent epithelial-to-mesenchymal transition and chemoresistance, arguing strongly against the use of drug holidays in cases of KRAS G13D amplification.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-019-09438-w

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Cited by

See all 52

Metadata

Authors
Sale, M. J., Balmanno, K., Saxena, J., Ozono, E., Wojdyla, K., McIntyre, R. E., Gilley, R., Woroniuk, A., Howarth, K. D., Hughes, G., Dry, J. R., Arends, M. J., Caro, P., Oxley, D., Ashton, S., Adams, D. J., Saez-Rodriguez, J., Smith, P. D., & Cook, S. J.
Venue
Nature Communications
Published
2019-05-02
Volume
10
Issue
1
Pages
2030-2030
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2943264785
Cited by
52
References
23
FWCI
1.93
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAFV600E amplification whereas KRASG13D amplification promotes EMT-chemoresistance. https://app.cochat.ai/papers/10.1038/s41467-019-09438-w
The paper
Sale, M. J., Balmanno, K., Saxena, J., Ozono, E., Wojdyla, K., McIntyre, R. E., Gilley, R., Woroniuk, A., Howarth, K. D., Hughes, G., Dry, J. R., Arends, M. J., Caro, P., Oxley, D., Ashton, S., Adams, D. J., Saez-Rodriguez, J., Smith, P. D., & Cook, S. J. (2019). MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAFV600E amplification whereas KRASG13D amplification promotes EMT-chemoresistance. Nature Communications. https://doi.org/10.1038/s41467-019-09438-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.